1. Signaling Pathways
  2. Immunology/Inflammation
  3. IRAK
  4. IRAK Isoform
  5. IRAK Inhibitor

IRAK Inhibitor

IRAK Inhibitors (33):

Cat. No. Product Name Effect Purity
  • HY-13329
    IRAK-1-4 Inhibitor I
    Inhibitor 99.90%
    IRAK-1-4 Inhibitor I is an inhibitor of interleukin-1 receptor-associated kinase 1/4 (IRAK 1/4) with IC50s of 0.2 μM and 0.3 μM, respectively.
  • HY-147264
    Edecesertib
    Inhibitor 99.86%
    Edecesertib (GS-5718) is a selective, potent, orally active IRAK-4 inhibitor. Edecesertib has anti-inflammatory activity. Edecesertib can be used for rheumatoid arthritis (RA) and lupus erythematosus (LE) research.
  • HY-101922
    IRAK4-IN-1
    Inhibitor 99.88%
    IRAK4-IN-1 is an interleukin-1 receptor associated kinase 4 (IRAK4) inhibitor with an IC50 of 7 nM.
  • HY-13276
    IRAK inhibitor 2
    Inhibitor 98.29%
    IRAK inhibitor 2 is IRAK4 (interleukin-1 receptor associated kinase 4) inhibitor .
  • HY-114181
    IRAK4-IN-4
    Inhibitor 99.85%
    IRAK4-IN-4 is an interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor extracted from patent CN107163044A, Compound15, has an IC50 of 2.8 nM. IRAK4-IN-4 also inhibits cyclic GMP-AMP synthase (cGAS) with an IC50 of 2.1 nM.
  • HY-18992R
    AS2444697 (Standard)
    Inhibitor
    AS2444697 (Standard) is the analytical standard of AS2444697 (HY-18992). This product is intended for research and analytical applications. AS2444697 is an orally active IRAK-4 inhibitor with an IC50 of 21 nM. AS2444697 potently inhibits human and rat IRAK-4 activity. AS2444697 exhibits renoprotective effects through anti-inflammatory action.
  • HY-151363
    IRAK4-IN-21
    Inhibitor 99.54%
    IRAK4-IN-21 (compound 17) is an orally active, potent and selective IRAK4 inhibitor with IC50 values of 5 and 56 nM for IRAK4 and TAK1, respectively. IRAK4-IN-21 effectively inhibits IL-23 production (IC50=0.17 μM) and can be used in studies of autoimmune diseases such as plaque psoriasis and psoriatic arthritis.
  • HY-130253
    IRAK4-IN-6
    Inhibitor 99.30%
    IRAK4-IN-6 is an orally efficacious and selective IRAK4 inhibitor with an IC50 of 4 nM, and targetes MyD88 L265P mutant diffuse large B cell lymphoma.
  • HY-148274
    KTX-582
    Inhibitor 98.65%
    KTX-582 is a potent IRAK4 degrader with DC50 values of 4 nM and 5 nM for IRAK4 and Ikaros, respectively. KTX-582 can induce apoptosis in MYD88MT DLBCL, and is efficient to induce in vivo tumor regressions in lymphoma model.
  • HY-13275
    IRAK inhibitor 1
    Inhibitor 99.83%
    IRAK inhibitor 1 is a potent IRAK-4 inhibitor with IC50 of 216 nM, is poorly active against JNK-1 and JNK-2 with IC50 of 3.801 μM, and >10 μM, respectively.
  • HY-W014223
    2,4′-Dihydroxybenzophenone
    Inhibitor 98.00%
    2,4′-Dihydroxybenzophenone (Ultraviolet absorber UV-0) occupies the hydrophobic pocket of MD2 and blocks the dimerization of TLR4. 2,4′-Dihydroxybenzophenone inhibits the LPS induced mtROS production, and LPS induced inflammatory response by downregulating pro-inflammatory mediators and decreasing the expression of MyD88, p-IRAK4, and NF-κB. 2,4′-Dihydroxybenzophenone is also a UV absorber.
  • HY-151365
    IRAK4-IN-22
    Inhibitor 98.20%
    IRAK4-IN-22 (compound 18) is an orally active, potent and selective IRAK4 inhibitor with IC50 values of 3 and 17 nM for IRAK4 and TAK1, respectively. IRAK4-IN-21 effectively inhibits IL-23 production (IC50=0.10 µM) and can be used in studies of autoimmune diseases such as plaque psoriasis and psoriatic arthritis.
  • HY-13278
    IRAK inhibitor 4
    Inhibitor 99.77%
    IRAK inhibitor 4 is an interleukin-1 receptor associated kinase 4(IRAK4) inhibitor.
  • HY-13280
    IRAK inhibitor 6
    Inhibitor 99.75%
    IRAK inhibitor 6 is an inhibitor of interleukin-1 receptor associated kinase 4 (IRAK-4) with IC50 of 160 nM.
  • HY-RS06899
    Irak4 Mouse Pre-designed siRNA Set A
    Inhibitor

    Irak4 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Irak4 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

  • HY-158434
    IRAK1-IN-1
    Inhibitor
    IRAK1-IN-1 (compound B8) is an orally active IRAK1 inhibitor. IRAK1-IN-1 inhibits the release of IL-6 with the IC50 values of 4.57 μM and 6.51 μM on mouse cells J774A. 1 and human cells THP-1, respectively. IRAK1-IN-1 alleviats LPS (HY-D1056)-induced acute lung injury (ALI) and DSS(HY-116282C)-induced colitis in mice.
  • HY-155132
    IRAK4-IN-28
    Inhibitor
    IRAK4-IN-28 (compound 42) is an orally active IRAK4 inhibitor (IC50=8.9 nM). IRAK4-IN-28 has binding affinity for IRAK4 with a Kd of 0.58 nM. IRAK4-IN-28 can be used in the research of inflammation and autoimmune diseases.
  • HY-RS06893
    IRAK1 Human Pre-designed siRNA Set A
    Inhibitor

    IRAK1 Human Pre-designed siRNA Set A contains three designed siRNAs for IRAK1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

  • HY-120041
    ND-2158
    Inhibitor
    ND-2158 is a competitive IRAK4 inhibitor, with the Ki of 1.3 nM. ND-2158 suppresses LPS-induced TNF production in human white blood cells, alleviated collagen-induced arthritis, and blocked gout formation in mouse models. ND-2158 has antitumor activity in vivo.
  • HY-RS06894
    Irak1 Mouse Pre-designed siRNA Set A
    Inhibitor

    Irak1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Irak1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.